Reported 8 months ago
On June 18, 2024, the new version of the U.S. Biosecurity Law seems to have alerted European, Korean, Japanese, and Taiwanese CDMO manufacturers to the potential for contract shifting, likely impacting the CDMO supply chain landscape. The Biosecure Act aims to prevent core data leakage in U.S. biopharmaceutical research, restricting interactions with Chinese biopharmaceutical companies. The growing importance of flexible manufacturing and stable supply chains post-COVID-19, along with geopolitical risks, is raising risk awareness in the biotech pharmaceutical CDMO industry. The industry is moving towards specialized manufacturing to focus on profit and avoid the risks of new drug development failure.
Source: YAHOO